Johnson & Johnson Innovation – JJDC, Inc.

Investing in and supporting the
global entrepreneurial community

Learn more

About us

Johnson & Johnson Innovation – JJDC, Inc. (JJDC) is focused on growing companies, not just investments. As the strategic venture arm of Johnson & Johnson, we pursue opportunities to solve critical healthcare needs. Our partners benefit from the full global capabilities of Johnson & Johnson as we collaborate to drive innovation. 

Strategic

JJDC finds transformative ideas and helps them mature into real solutions for today’s patients. 

Guided by a clear, consistent investment strategy aligned with scientific goals, JJDC works hand-in-hand with partners to navigate the path to creating breakthrough health innovations. 

We invest across sectors—pharmaceuticals, medical devices and consumer healthcare—and at all stages, from seed-level startups to Series B and beyond.  

All of our portfolio companies receive the same unwavering commitment. We take a long-term approach, deploying the full capabilities of the Johnson & Johnson family of companies, including discovery, clinical development, regulatory affairs, manufacturing and commercialization. 

Our team includes leaders in the healthcare and technology communities, many with deep R&D experience. This gives us the ability to understand our partners and provide the help they need. 

Every opportunity is unique, with tailored roles and terms that provide the best path to success. 

Team

  • Tom Heyman
    President JJDC
  • Jeanne Bolger
    Vice President, Venture Investments
  • Marianne De Backer
    Vice President, Venture Investments
  • Maciek Drozdz
    Principal, Venture Investments
  • Stacy Feld
    Vice President of Consumer Venture Investments and External Innovation
  • V. Kadir Kadhiresan
    Vice President, Venture Investments
  • Bo Liu
    Principal, Venture Investments, JJDC
  • Vijay Murthy
    Principal, Venture Investments
  • Marian Nakada
    Vice President, Venture Investments
  • Renee Compton Ryan
    Vice President, Venture Investments
  • Asish K. Xavier
    Vice President, Venture Investments
  • Zeev Zehavi
    Vice President, Venture Investments
  • Close

    Tom Heyman

    President JJDC

    Tom Heyman is President, Johnson & Johnson Development Corporation (JJDC), part of Johnson & Johnson Innovation. As head of JJDC, Tom will chair the board of JJDC, which represents the oldest and most reputable corporate venture fund in the life science industry.

    Tom will continue his position as CEO of Janssen Pharmaceutica NV in Belgium, and he continues to be responsible for campus leadership in Beerse, Belgium, as well as the development and execution of a long-term organizational and talent strategy. Tom was appointed Chairman of the Board of Directors, Janssen Pharmaceutica in March 2012. He is a member of the Board of Directors VOKA, the Flemish Industry Association, Belgium, and a member of the Board of Directors of Innotek. As of April 2012, he is a member of the Board of Directors and the General Assembly of IMEC.

    Tom started his career with Johnson & Johnson in the Legal Department of Janssen Pharmaceutica NV in 1982, where he supported legal and licensing activities. In 1990, he became Vice-President of Corporate Development at Ortho Pharmaceutical Corporation, and was later appointed Head of Global Business Development for the Pharmaceutical Group. In his 25 years in Business Development, Tom and his Group entered into hundreds of transactions for both early and late stage Pharmaceutical products and technologies including IMBRUVUCA®, daratanumab, INVOKANA®, etc. He was also responsible for acquiring several key companies for J&J including Aragon Pharmaceuticals, Covagen and Alios Biopharma. Tom has been a member of the Pharmaceuticals Group Operating Committee (GOC), and he also served as Head of the CNS/IM Research & Early Development (RED) organization.

  • Close

    Jeanne Bolger,
    MB BCh

    Vice President, Venture Investments

    Jeanne joined Johnson & Johnson Development Corporation (JJDC) as Vice President, Venture Investments, in February 2013.  She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne’s responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.

    Jeanne has over 25 years of pharmaceutical industry experience in management roles across R+D, Commercial and Business Development.  She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK.

    In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer’s disease.

    Jeanne received her medical degree from University College Dublin.  She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA).  She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI).  She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres.  She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

  • Close

    Marianne De Backer,
    PhD, MBA

    Vice President, Venture Investments

    Marianne De Backer, PhD, is Vice President of Venture Investments at Johnson & Johnson Innovation – JJDC, Inc. (JJDC).  She is based in California. 

    During her career at Johnson & Johnson, Marianne held roles in research, technology licensing and led a commercial business unit team to her most recent role in Janssen Business Development responsible for late-stage pharmaceutical deals.  As a scientist and R&D group leader, Marianne was named as inventor on five patent applications. In her most recent role, Marianne was with Janssen Business Development leading the Infectious Diseases & Vaccines (IDV) TA and Emerging Markets (licensing, mergers & acquisition, and alliance management).  Under her direct leadership over the past several years, the IDV pipeline grew significantly through creative partnerships.

    Marianne holds an MBA from Erasmus University Rotterdam, a PhD in Biotechnology from the University of Ghent, a MSc in Molecular Biology from the University of Brussels, and an engineering degree in Biochemistry from the IH Ghent. 

  • Close

    Maciek Drozdz,
    PhD, MBA

    Principal, Venture Investments

    Maciek Drozdz is a Principal of Venture Investments for Johnson and Johnson Development Corporation (JJDC) and joined in 2017. Maciek is based in London at the Johnson and Johnson Innovation Centre.

    Maciek has spent 10 years working in the Venture Capital and biotech industry. Most recently he served as a CEO of Antagonis Biotherapeutics, an immuno-oncology company in Graz, Austria. Previously he was investment manager at Entrepreneurs Fund LLP, investment director at MCI Bioventures and an analyst at Atlas Venture. Maciek has served on a number of boards of private and public companies across several countries.

    Maciek received his Master’s Degree in molecular biology from the Adam Mickiewicz University in Poznan, Poland followed by a Doctorate at the University of Heidelberg in Germany. He has also worked as a Postdoc at the Friedrich Miescher Institute in Basel, Switzerland. Maciek holds an MBA degree from the Said Business School in Oxford. He lectured a course in “Innovation in Biotechnology” at Adam Mickiewicz University.

  • Close

    Stacy Feld

    Vice President of Consumer Venture Investments and External Innovation

    Stacy is Vice President of Consumer Venture Investments and External Innovation with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in California.  

    Stacy leads consumer and health technology venture investing and is responsible for all equity investments across the Consumer global franchises, as well as enterprise areas that include Health and Wellness Solutions and Health Technology.   

    Stacy has nearly two decades of diverse experience in the healthcare, life sciences and consumer sectors as a transactional attorney, business development executive, venture investor and business strategist.

    Previously, Stacy was a partner at Physic Ventures, a venture capital firm investing in health and sustainability, where she led investments in personalized health solutions that empower consumers to improve their health and wellbeing.  Stacy has also been active in the design and execution of science-enabled innovation strategies, business incubation and spin-off opportunities, advising senior management of global enterprises in the CPG industry, as well as pre-commercial and commercial-stage companies in the personalized health and medical technology sectors. 

    Prior to joining Physic Ventures, Stacy held leadership positions in the business development groups at Genentech and Third Wave Technologies and was a technology transactions attorney at Wilson, Sonsini, Goodrich & Rosati.  Stacy serves as an advisor on the Springboard Enterprises Life Sciences Council and to the UCSF Clinical and Translational Research Institute T1 Catalyst Program.

    Stacy earned her B.A. in Sociology from the University of Pennsylvania and received her J.D. from Vanderbilt Law School.

  • Close

    V. Kadir Kadhiresan,
    PhD

    Vice President, Venture Investments

    V. Kadir Kadhiresan, PhD, Vice President, Venture Investments, joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2007. He serves on the boards of JJDC portfolio companies and is based in Boston, Massachusetts.

    Dr. Kadhiresan has more than a decade of operational experience in various functional roles including research, product development, and business development. Before joining JJDC, as head of Business Development at Guidant, Inc., now Boston Scientific, Inc., Dr. Kadhiresan led several transactions to access novel medical device technologies with venture investments, M&As, licensing and joint ventures. Prior to entering business development, he led the research and development of multiple early-stage technologies and products in cardiac rhythm management and heart failure.  Dr. Kadhiresan was instrumental in the development of the cardiac resynchronization therapy for heart failure, now a multi-billion dollar worldwide market. At Heart Rhythm Technologies, a subsidiary of Guidant, he led the development of an ablation technology for treatment of atrial fibrillation and raised venture financing for the project. In addition, Dr. Kadhiresan is an inventor on more than 40 patents and has published several articles in peer-reviewed journals.

    Dr. Kadhiresan received a PhD and Master of Science in Biomedical Engineering from the University of Michigan, Ann Arbor, a Master of Business Administration from the Kellogg School of Management at Northwestern University, and a Bachelor of Science in Electrical Engineering from National Institute of Technology (REC), Trichy, India.

  • Close

    Bo Liu,
    PhD, MBA

    Principal, Venture Investments, JJDC

    Bo joined Johnson & Johnson Development Corporation (JJDC) in January 2013. He is based in China and focuses on the life science investment opportunities in Asia Pacific regions.

    Prior to joining JJDC, Bo was Director of Business Development and Strategic Planning with GlaxoSmithKline Consumer Healthcare China, where he led key strategic initiatives in mergers and acquisitions, licensing and portfolio optimization. Prior to GSK, he worked in the corporate development and strategy group with Charles River Laboratories in Boston, where he played an instrumental role in several strategic transactions. Bo has executed M&A and licensing transactions in the US, Europe and Asia with total considerations over $2 billion.

    Bo received a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago, and a Master of Medicine from the seven-year program of Tongji Medical University in Wuhan, China. He received residency training in Urology at Union Hospital of Tongji Medical University. 

  • Close

    Vijay Murthy,
    PhD

    Principal, Venture Investments

    Vijay is a Principal of Venture Investments at Johnson & Johnson Innovation, JJDC. Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in California. Vijay focuses on venture investments in biotechnology, pharmaceuticals, and diagnostics.

    Prior to joining JJDC, Vijay was a Director of Ventures & Early-Stage Collaborations at AbbVie, where he focused on venture investments and preclinical business development transactions. Prior to AbbVie, Vijay was co-founder and CEO of an early-stage peptide manufacturing company, and an independent consultant to several top-tier life sciences venture capital firms and biopharmaceutical companies. Previously, Vijay led business development at Enlight Biosciences, a seed-stage venture creation firm founded by PureTech Health and partnered with 7 major biopharmaceutical companies. He started his business career as a strategy consultant at the Boston Consulting Group (BCG).

    Vijay earned an AM and a PhD in biophysical chemistry from Harvard University, and a BS in chemistry with highest honors and highest distinction from the University of North Carolina at Chapel Hill.

  • Close

    Marian Nakada,
    PhD

    Vice President, Venture Investments

    Marian is a Vice President in Venture Investments at Johnson & Johnson Development Corporation, and is based in the Johnson & Johnson Innovation Center in Boston.  She focuses primarily on pharmaceuticals (small molecules and biologics) and diagnostics.

    Previously, Marian was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy.

    Marian joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Marian joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor's technologies were competitive with the industry.

    Marian has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.

  • Close

    Renee Compton Ryan

    Vice President, Venture Investments

    Renee is Vice President of Investments at the Johnson & Johnson Development Corporation, and is based at the Johnson & Johnson Innovation Center in California. Renee supports the investments for our Medical Devices and Diagnostics businesses and is a passionate supporter of medical innovation.

    Formerly, Renee was a Managing Director at Baird in Palo Alto, CA overseeing the medical device investment banking practice.  Prior to Baird, Renee oversaw the build out of the West Coast healthcare investment banking practice at Jefferies & Co.  In total, Renee has approximately 20 years of healthcare investment banking experience at firms such as Goldman Sachs and Credit Suisse.  She has structured over $15 Billion of transactions during this time including M&A, venture financing and public offerings of debt and equity.

    Renee earned her B.A. in economics at Georgetown University in Washington, D.C., and an MBA from Columbia University.

  • Close

    Asish K. Xavier,
    PhD, MBA

    Vice President, Venture Investments

    Asish is with Johnson & Johnson Development Corporation (JJDC) and is based in the Johnson & Johnson Innovation Center in California.  Asish focuses on venture investments in biotechnology and diagnostics.  Asish joined JJDC in 2004, and has invested in over a dozen biotech and diagnostics deals.

    Asish previously worked in business development at BioRexis Pharmaceutical Corporation which was acquired by Pfizer in 2007.  While at BioRexis, he assisted the company in raising a $30 million second round of financing.  Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc.

    Asish received a PhD from the University of Houston in Chemical Engineering, and a MBA from the Wharton School of the University of Pennsylvania, where he graduated with honors.  He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India.  Asish was a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.

  • Close

    Zeev Zehavi,
    MBA

    Vice President, Venture Investments

    Zeev Zehavi is Vice President of Venture Investments for Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and joined in 1999. He is based out of offices in Israel and Belgium.

    Mr. Zehavi’s background covers an extensive array of health care and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years before starting his own consulting business, Pharma Zee, Ltd. While operating this consultant business for medical device and pharmaceutical start-up companies, Mr. Zehavi initiated contacts with various Johnson & Johnson companies.

    Mr. Zehavi holds a Bachelor of Science from Hebrew University of Jerusalem and a Master of Business Administration in Marketing and Finance from Tel Aviv University. He is fluent in Hebrew, English, and Arabic.

Approach

We’re positively impacting human health through innovation. To do this, we identify the best opportunities across all sectors and allow innovators to leverage Johnson & Johnson’s many resources.

We’ve Been There Before

Our highly experienced team hails from throughout the healthcare and technology venture communities, many of us bringing deep R&D experience in addition to investment acumen. Just like you, we are entrepreneurs, scientists and studied risk-takers. Our team’s unique vantage point gives us an exceptional ability to understand the challenges and provide the right kind of help at the right time.    

Investing With Impact 

We have dedicated teams focused on investing at all stages of innovation, and across all four sectors: pharmaceuticals, medical devices, consumer health and global public health. We seek innovations with potential to make a transformational impact in the health and lives of people around the globe. 

If your early-stage company is looking to advance a program that is pre-proof of concept in humans, connect with one of our Johnson & Johnson Innovation Centers, located around the globe in the life science hot spots of Asia Pacific, Boston, California and London.

Each Investment Is Unique

At JJDC, there’s no such thing as a one-size-fits-all approach. We understand that each idea is unique, requiring an equally distinct investment strategy. We customize every deal to the opportunity, ranging from Seed and Series A investments in the earliest-stage startups to Series B investments and beyond in more mature companies. We also make private investments in public equity.

Creating Thriving Enterprises

For more than 40 years, JJDC has made investments in hundreds of innovative companies across pharmaceuticals, medical devices and consumer healthcare. Once we invest, we’re committed to you. We believe in value-add investing, playing an active role in providing strategic direction and enabling access to internal experts across the Johnson & Johnson Family of Companies.

Focus Areas

JJDC is seeks ideas that align with our business priorities in our Pharmaceuticals, Consumer and Medical Devices sectors. In each sector, we focus on specific therapeutic areas of interest that have the greatest potential to improve the lives of patients and consumers.

CLICK a business area of interest below
  • Consumer
  • Medical Devices
  • Pharmaceuticals
  • Global Public Health
CLICK on a circle to see the areas we are targeting
  • Healthy Sleep Habits, Massage and Sensory Enrichment, Safe Bug Care Products, Environmental Skin Protection (Germs, Sun, Pollution), Ease of Use Solutions
    Baby Care
    Baby Care
  • Skin, Acne, Blackheads, Oily Skin, Aging Prevention, Environmental Protection, Sunscreen Compliance and Sensory Experience, Body hydration and skin barrier protection, Therapeutic Hair Care, Novel Hair Growth Solutions
    Beauty
    Beauty
  • Bug Bites, Burns, Cracked Skin, Instant, Long-Lasting Pain Relief, Infection Reduction, Protection, Accelerate & Monitoring Healing, Ease of Use Solutions
    Compromised skin
    Compromised skin
  • Novel Solutions for Feminine Hygiene, Fit and Comfort, Discretion, Health Sensing & Promoting
    Feminine Personal Care
    Feminine Personal Care
  • Enamel Repair, Microbial Control for Prevention of Oral Conditions, Functional Barriers for Tooth Protection, Whitening Technologies, Oral Health Sensing
    Oral Care
    Oral Care
  • Pain: Episodic and Recurrent Head and Body Pain,
    Cough & Cold: Multi-symptom Head Cold, Cough and Sore Throat,
    Digestive Health: IBS, Diarrhea, Constipation, Indigestion, Dehydration, Heartburn,
    Allergy: Episodic Respiratory, Skin/Atopic, and Food Allergies,
    Smoking Cessation: Nicotine replacement therapy, non-nicotine drugs, devices, behavioral programs
    OTC
    OTC

Contact

Make the Connection

We look forward to our first discussion.  If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

contact

Accelerators

Close
Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
mail@www.neomed.ca
www.neomed.ca
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.